FDA Approves Gilead’s Bixlenvo for HIV Treatment
Foster City, California, August 27, 2026 Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Gilead Sciences
Advertisement
Gilead Sciences Secures CHMP Support for Trodelvy Plus KEYTRUDA
FOSTER CITY, Calif., July 24, 2026 Gilead Sciences announced that the European Medicines Agency’s Committee for Medicinal Products for...
Gilead Sciences and Merck & Co. Deliver Positive ISLEND Phase 3 Results
FOSTER CITY, Calif. & RAHWAY, N.J., July 22, 2026 Gilead Sciences and Merck announced detailed results from the Phase...
Gilead Sciences Presents New HIV Prevention and Treatment Data at AIDS 2026
FOSTER CITY, Calif., July 22, 2026 Gilead Sciences announced an extensive scientific program for the 26th International AIDS Conference...
Gilead Sciences Wins FDA Approval for Trodelvy in First-Line mTNBC
FOSTER CITY, Calif., June 24, 2026 Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Advertisements
Merck and Gilead End KEYNOTE-D46 Study Update
RAHWAY, N.J. and FOSTER CITY, Calif., June 8, 2026 Merck (NYSE: MRK) and Gilead Sciences (Nasdaq: GILD) announced the...
Gilead’s Livdelzi Achieves Key Phase 3 PBC Trial Goal
FOSTER CITY, California, USA, June 2, 2026 Gilead Sciences has announced positive topline results from the Phase 3 IDEAL...
Gilead Reports Strong Long-Term Livdelzi PBC Data
FOSTER CITY, Calif., May 28, 2026 Gilead Sciences announced new interim findings from the ongoing Phase 3 ASSURE study...
Gilead’s Trodelvy Wins CHMP Support in 1L TNBC
FOSTER CITY, Calif., May 25, 2026 Gilead Sciences announced that the European Medicines Agency’s Committee for Medicinal Products for...
FDA Grants Historic Approval to Gilead’s Hepcludex for HDV
Foster City, California, USA – May 21, 2026 Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration...
Advertisement
